ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2

Original text here LEIDEN, Netherlands and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient dosed in the Phase 1/2 STELLAR clinical trial for QR-421a in patients with Usher syndrome type 2 or non-syndromic retinitis pigmentosa (RP).
Read

Will my children have Usher Syndrome?

This text is taken from Usher Syndrome Coalition website, where you can find more information about genetics for Usher syndrome   Children receive one copy of each chromosome from their mother (shown in green) and one copy from their father (shown in blue).
Read

Yellow and .. blue. Autumn contrasts

NoisyVision has been promoting the #YellowTheWorld campaign for several years, to paint the world Yellow. We are sure that a more yellow world would be not only more visible to people with low vision, but also more beautiful, lively, joyful and positive.
Read